Journal article
Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years
Abstract
Purpose MA.17R was a Canadian Cancer Trials Group-led phase III randomized controlled trial comparing letrozole to placebo after 5 years of aromatase inhibitor as adjuvant therapy for hormone receptor-positive breast cancer. Quality of life (QOL) was a secondary outcome measure of the study, and here, we report the results of these analyses. Methods QOL was measured using the Short Form-36 (SF-36; two summary scores and eight domains) and …
Authors
Lemieux J; Brundage MD; Parulekar WR; Goss PE; Ingle JN; Pritchard KI; Celano P; Muss H; Gralow J; Strasser-Weippl K
Journal
Journal of Clinical Oncology, Vol. 36, No. 6,
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
February 20, 2018
DOI
10.1200/jco.2017.75.7500
ISSN
0732-183X